Ergomed plc Issue of Consideration Shares (0622H)
04 Abril 2022 - 1:01AM
UK Regulatory
TIDMERGO
RNS Number : 0622H
Ergomed plc
04 April 2022
Issue of Consideration Shares to Founder of MedSource
Guildford, UK - 4 April 2022 : Ergomed plc (LSE: ERGO)
("Ergomed" or the "Company"), a company focused on providing
specialised services to the pharmaceutical industry, today
announces that application has been made to AIM for the admission
of 155,558 new ordinary shares of 1p each in the capital of the
Company ("Consideration Shares").
The Consideration Shares are being issued to Eric Lund, the
founder and former shareholder of MS Clinical Services, LLC
("MedSource"), as part of the consideration for the acquisition of
MedSource, announced on 14 December 2020 . Under the terms of the
acquisition, part of the consideration payable for MedSource was to
be satisfied by the issue of up to $1.8 million in Ergomed shares,
subject to reduction for breaches of representations and
warranties. Each Consideration Share has a value of GBP8.7555, such
price being based on the average daily closing price of the
Company's shares for the 30 days preceding the acquisition, in
accordance with the terms of the acquisition documents. The
Consideration Shares are subject to a six month lock-in, followed
by a six month orderly market provision, from the date of
issue.
Admission to trading on AIM of the Consideration Shares
("Admission") is expected to occur on 5 April 2022. Following
Admission, the Consideration Shares will rank pari passu in all
respects with the Company's existing ordinary shares.
Following Admission, the total number of ordinary shares with
voting rights in issue will be 49,507,129. This figure may be used
by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the Company under the
Financial Conduct Authority's Disclosure Guidance and Transparency
Rules.
ENDS
Enquiries :
Ergomed plc Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets &
Strategy)
Numis (Nominated Adviser and Joint Broker) Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP (Joint Broker) Tel: +44 (0) 20 7418 8900
James Steel / Dr. Christopher Golden
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal / Angela Gray
ergomed@consilium-comms.com
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO) and mission-critical regulatory compliance and consulting
services under the ADAMAS brand. For further information, visit:
http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCIJMBTMTIMTRT
(END) Dow Jones Newswires
April 04, 2022 02:01 ET (06:01 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024